HUP0203441A2 - L-karnitin és alkanoil-származékai alkalmazása ozmózisnyomás-szabályozó szerként és a gyógyászati alkalmazásra szánt oldatok - Google Patents

L-karnitin és alkanoil-származékai alkalmazása ozmózisnyomás-szabályozó szerként és a gyógyászati alkalmazásra szánt oldatok

Info

Publication number
HUP0203441A2
HUP0203441A2 HU0203441A HUP0203441A HUP0203441A2 HU P0203441 A2 HUP0203441 A2 HU P0203441A2 HU 0203441 A HU0203441 A HU 0203441A HU P0203441 A HUP0203441 A HU P0203441A HU P0203441 A2 HUP0203441 A2 HU P0203441A2
Authority
HU
Hungary
Prior art keywords
carnitine
solutions
alkanoyl derivatives
medical use
osmotic agents
Prior art date
Application number
HU0203441A
Other languages
English (en)
Inventor
Arduino Arduini
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of HUP0203441A2 publication Critical patent/HUP0203441A2/hu
Publication of HUP0203441A3 publication Critical patent/HUP0203441A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány L-karnitin és alkanoilszármazékai alkalmazására vonatkozik- adott esetben gyógyászatilag elfogadható sók formájában -ozmózisnyomás-szabályozó szerként gyógyászati alkalmazásra, különösenperitoneális dialízisre szánt oldatokban. A találmány tárgyát képeziktovábbá gyógyászati alkalmazásra szánt oldatok, amelyekben azozmotikus szer L-karnitin vagy annak alkanoil-származékai, adottesetben egy másik vagy több másik ismert ozmotikus szerrelkombinációban; valamint ezeket az oldatokat tartalmazó peritoneálisdialízisre alkalmas tartályok. Ó
HU0203441A 1999-10-11 1999-10-11 Use of l-carnitine and its alkanoyl derivatives as osmotic agents and solutions for medical use HUP0203441A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT1999/000317 WO2001026649A1 (en) 1999-10-11 1999-10-11 Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use

Publications (2)

Publication Number Publication Date
HUP0203441A2 true HUP0203441A2 (hu) 2003-03-28
HUP0203441A3 HUP0203441A3 (en) 2004-01-28

Family

ID=11333127

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203441A HUP0203441A3 (en) 1999-10-11 1999-10-11 Use of l-carnitine and its alkanoyl derivatives as osmotic agents and solutions for medical use

Country Status (20)

Country Link
US (2) US6822002B1 (hu)
EP (1) EP1220670B1 (hu)
JP (1) JP4638106B2 (hu)
KR (1) KR100642731B1 (hu)
AT (1) ATE336243T1 (hu)
AU (1) AU1073400A (hu)
CA (1) CA2386826C (hu)
CY (1) CY1106203T1 (hu)
CZ (1) CZ303870B6 (hu)
DE (1) DE69932860T2 (hu)
DK (1) DK1220670T3 (hu)
ES (1) ES2270620T3 (hu)
HK (1) HK1046090B (hu)
HU (1) HUP0203441A3 (hu)
MX (1) MXPA02003635A (hu)
PL (1) PL213131B1 (hu)
PT (1) PT1220670E (hu)
SI (1) SI1220670T1 (hu)
SK (1) SK288072B6 (hu)
WO (1) WO2001026649A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770148B1 (en) 1998-12-04 2004-08-03 Baxter International Inc. Peritoneal dialysis solution containing modified icodextrins
ITRM20010337A1 (it) * 2001-06-14 2002-12-16 Sigma Tau Ind Farmaceuti Soluzione per la conservazione e perfuzione di organi in attesa che vengano trapiantati.
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US7053059B2 (en) 2003-07-25 2006-05-30 Baxter International Inc. Dialysis solutions with reduced levels of glucose degradation products
ITRM20040346A1 (it) 2004-07-13 2004-10-13 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.
JP2006075195A (ja) * 2004-09-07 2006-03-23 Jms Co Ltd Ｌカルニチン含有腹膜透析液
TWI388318B (zh) * 2005-03-10 2013-03-11 Sigma Tau Ind Farmaceuti 具有改良之生物相容性的含有肉毒鹼之腹膜透析溶液
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
RU2426561C2 (ru) * 2006-01-30 2011-08-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и устройство для перитонеального диализа
US8876753B2 (en) 2006-01-30 2014-11-04 The Regents Of The University Of California Peritoneal dialysis methods and apparatus
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
TWI454287B (zh) * 2012-11-21 2014-10-01 Taipei Veteran General Hospital 治療纖維化之透析液
US9539411B2 (en) 2013-03-13 2017-01-10 W. L. Gore & Associates, Inc. Deconstructable endoluminal devices and related systems and methods
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液
CN103463081B (zh) * 2013-09-27 2015-10-21 华仁药业股份有限公司 腹膜透析液
DE102015014699A1 (de) * 2015-11-13 2017-05-18 Fresenius Medical Care Deutschland Gmbh Dialyselösung mit wenigstens einem Osmotikum
EP3912656A1 (en) 2020-05-19 2021-11-24 CoreQuest Sagl Peritoneal dialysis solution
EP4029507A1 (en) 2021-01-19 2022-07-20 Iperboreal Pharma Srl Peritoneal dialysis solution for hypertensive subjects

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
CH664374A5 (de) * 1985-02-27 1988-02-29 Lonza Ag Verfahren zur herstellung von l-carnitin auf mikrobiologischem weg.
JPH04320145A (ja) * 1991-04-19 1992-11-10 Ricoh Co Ltd ファクシミリ装置
IT1261695B (it) 1993-06-02 1996-05-29 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono.
IT1283137B1 (it) 1996-07-09 1998-04-07 Bieffe Medital Spa Agenti osmotici alternativi e relative soluzioni per dialisi peritoneale
JPH1094598A (ja) 1996-07-31 1998-04-14 Baxter Internatl Inc 腹膜透析液
US5973004A (en) * 1997-04-04 1999-10-26 Howard; James R. L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US6482585B2 (en) * 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
GB9714218D0 (en) 1997-07-04 1997-09-10 Allied Therapeutics Ltd Peritoneal dialysis fluid
JPH1149671A (ja) 1997-08-06 1999-02-23 Baxter Internatl Inc 腹膜透析液
US6537976B1 (en) * 1997-08-07 2003-03-25 Ajay Gupta Dialysis solutions containing water soluble vitamins and nutrients
JPH1171286A (ja) 1997-08-29 1999-03-16 Terumo Corp 腹膜透析液
JPH1171273A (ja) 1997-08-29 1999-03-16 Terumo Corp 腹膜透析液
WO1999035917A1 (en) * 1998-01-15 1999-07-22 Edward Hirschberg Methods of infusing phytochemicals, nutraceuticals, and other compositions into food products

Also Published As

Publication number Publication date
US7932291B2 (en) 2011-04-26
CZ303870B6 (cs) 2013-06-05
SI1220670T1 (sl) 2006-12-31
KR100642731B1 (ko) 2006-11-03
MXPA02003635A (es) 2002-10-23
JP2003511413A (ja) 2003-03-25
CA2386826A1 (en) 2001-04-19
CZ20021063A3 (cs) 2002-08-14
DK1220670T3 (da) 2006-12-18
EP1220670A1 (en) 2002-07-10
SK4432002A3 (en) 2002-08-06
HK1046090A1 (en) 2002-12-27
DE69932860D1 (de) 2006-09-28
WO2001026649A1 (en) 2001-04-19
AU1073400A (en) 2001-04-23
HUP0203441A3 (en) 2004-01-28
EP1220670B1 (en) 2006-08-16
US20050085542A1 (en) 2005-04-21
JP4638106B2 (ja) 2011-02-23
SK288072B6 (sk) 2013-05-03
KR20020038809A (ko) 2002-05-23
PL213131B1 (pl) 2013-01-31
CA2386826C (en) 2010-04-20
DE69932860T2 (de) 2007-08-30
PL354414A1 (en) 2004-01-12
US6822002B1 (en) 2004-11-23
HK1046090B (zh) 2007-06-29
CY1106203T1 (el) 2011-06-08
PT1220670E (pt) 2006-10-31
ATE336243T1 (de) 2006-09-15
ES2270620T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
HUP0203441A2 (hu) L-karnitin és alkanoil-származékai alkalmazása ozmózisnyomás-szabályozó szerként és a gyógyászati alkalmazásra szánt oldatok
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
SE9503143D0 (sv) New preparation
BRPI0407352A (pt) Composição para o cuidado oral, e, métodos para efetuar a estabilidade aumentada em uma composição oral contendo enzimas, e para a preparação de uma composição para o cuidado oral aquosa
AU2003262262A1 (en) Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
MY130441A (en) Solutions containing epinastin
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
WO2003015779A3 (de) Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol
AR033325A1 (es) Composicion que comprende una carnitina y glutationa , util para incrementar la absorcion de la glutationa y sinergizar sus efectos, un complemento dietario, medicamento, la utilizacion de una composicion de combinacion para preparar un complemento dietario o un medicamento
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
MY118345A (en) Repinotan kit
PL346764A1 (en) New oral formulation for 5-ht4
AR023815A1 (es) Solucion oral de prucalopride
YU13599A (sh) Primena farmaceutske kompozicije za dobijanje leka u obliku gela
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
CA2376033A1 (en) Use of l-carnitine and its alkanoyl derivatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy
NO20005492L (no) Dekstrinholdig preparat for prevensjon av kirurgiske adhesjoner
EP0355453A3 (en) Use of 3-hydroxybutyric acid as an energy source
AU6846300A (en) Use of cyamemazine for cold turkey benzodiazepine treatment
PL350413A1 (en) Pharmaceutical effervescent formulation containing metamizol
GR20010100390A (el) Χρηση του diclofenac h αποδεκτων αλατων αυτου για την αντιμετωπιση των εγκαυματων.
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada
EE200300096A (et) Arginiini ja selle farmatseutiliselt vastuvõetavate soolade kasutamine, antineoplastilist toimeainet ja arginiini sisaldava intravenoosselt manustatava preparaadi kasutamine, toode või komplekt kasutamiseks vähiravis ja preparaat intravenoosseks manu

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished